Regulatory FDA weighs drug repurposing pathway for underserved diseases Pharmaceutical TechnologyApproved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunitiesNext: A year after Vertex’s big launch, pain drug research faces a pivotal moment Related Stories Regulatory Bayer gets swift review for Kerendia in type 1 diabetes pharminent May 21, 2026 Regulatory Pazdur declines to announce candidacy for vacated FDA commissioner role pharminent May 20, 2026 Regulatory VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain pharminent May 19, 2026
